Open AccessSerum anti‐LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases
Author(s) -
Sumazaki Makoto,
Shimada Hideaki,
Ito Masaaki,
Shiratori Fumiaki,
Kobayashi Eiichi,
Yoshida Yoichi,
Adachi Akihiko,
Matsutani Tomoo,
Iwadate Yasuo,
Mine Seiichiro,
Machida Toshio,
Kamitsukasa Ikuo,
Mori Masahiro,
Sugimoto Kazuo,
Uzawa Akiyuki,
Kuwabara Satoshi,
Kobayashi Yoshio,
Ohno Mikiko,
Nishi Eiichiro,
Maezawa Yoshiro,
Takemoto Minoru,
Yokote Koutaro,
Takizawa Hirotaka,
Kashiwado Koichi,
Shin Hideo,
Kishimoto Takashi,
Matsushita Kazuyuki,
Kobayashi Sohei,
Nakamura Rika,
Shinmen Natsuko,
Kuroda Hideyuki,
Zhang XiaoMeng,
Wang Hao,
Goto Kenichiro,
Hiwasa Takaki
Publication year - 2020
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14652
Subject(s) - medicine , antibody , biomarker , antigen , immunology , cancer , serology , recombinant dna , biology , biochemistry , gene
Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay‐linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti‐human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low‐density lipoprotein receptor–related protein–associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S‐transferase–fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis‐related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well‐known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.